Table 1 Phase 1 studies of newer radiosensitizers including platinum compounds
From: Radiosensitizers in cervical cancer. Cisplatin and beyond
Agent [ref] | Radiation | Dose |
|---|---|---|
CDDP (daily) [29] | EBRT | 8 mg/m2 |
Carboplatin (CI) [37] | EBRT | 12 mg/m2 |
Carboplatin (weekly) [39] | EBRT | 133 mg/m2 |
Topotecan daily on days 1–5 & 22–26 [70] | EBRT | 1 mg/m2 |
Topotecan daily on days 1–5 [71] | Brachy | 0.5 mg/m2 |
Topotecan plus CDDP | EBRT | no results yet |
Irinotecan plus CDDP | EBRT | no results yet |
Vinorelbine (weekly) [78]* Vinorelbine + paclitaxel | EBRT | 25 mg/m2 to toxic |
Paclitaxel (weekly) + CDDP (every 21 days) [85] | EBRT | 50 mg/m2 and 50 mg/m2 |
Paclitaxel (weekly) + CDDP (weekly) [86] | EBRT | 50 mg/m2 and 30 mg/m2 |
Paclitaxel (weekly) +Carboplatin (weekly) [87] | EBRT | 50 mg/m2 and 2.5 AUC |
Gemcitabine (weekly) [94] | EBRT | DLT not reached at 150 mg/m2 |
CDDP (weekly) +Gemcitabine (weekly) [100] | EBRT | 40 mg/m2 and 125 mg/m2 |
Gemcitabine first (weekly) +CDDP (weekly) [103] | EBRT | 50 mg/m2 and 40 mg/m2 to toxic |
Capecitabine (twice daily) [109] | EBRT | 825 mg/m2 |
Capecitabine +CDDP (twice daily) [113] | EBRT | 825 mg/m2 |